OBJECTIVE: This literature review details the history, pharmacokinetics, and utility of (18)F-sodium fluoride (Na(18)F) PET/CT in detecting osseous metastases compared with the current standard of care, technetium-99m methylene diphosphonate ((99m)Tc-MDP) bone scintigraphy. Additional discussion highlights solutions to impediments for broader implementation of this modality and insight into the complementary roles of (18)F-FDG PET/CT and Na(18)F PET/CT in oncology imaging, including preliminary data for combined Na(18)F and FDG PET/CT. CONCLUSION: Na(18)F PET/CT is the most comprehensive imaging modality for the evaluation of osseous metastatic disease. Although further data acquisition is necessary to expand cost-benefit analyses of this imaging agent, emerging data reinforce its diagnostic advantage, suggest methods to mitigate impediments to broader utilization of Na(18)F PET/CT, and introduce a potentially viable technique for single-session combined Na(18)F and FDG PET/CT staging of soft-tissue and osseous disease.
OBJECTIVE: This literature review details the history, pharmacokinetics, and utility of (18)F-sodium fluoride (Na(18)F) PET/CT in detecting osseous metastases compared with the current standard of care, technetium-99m methylene diphosphonate ((99m)Tc-MDP) bone scintigraphy. Additional discussion highlights solutions to impediments for broader implementation of this modality and insight into the complementary roles of (18)F-FDG PET/CT and Na(18)F PET/CT in oncology imaging, including preliminary data for combined Na(18)F and FDG PET/CT. CONCLUSION: Na(18)F PET/CT is the most comprehensive imaging modality for the evaluation of osseous metastatic disease. Although further data acquisition is necessary to expand cost-benefit analyses of this imaging agent, emerging data reinforce its diagnostic advantage, suggest methods to mitigate impediments to broader utilization of Na(18)F PET/CT, and introduce a potentially viable technique for single-session combined Na(18)F and FDG PET/CT staging of soft-tissue and osseous disease.
Entities:
Keywords:
PET; bone metastasis; cancer staging; oncology; sodium fluoride
Authors: Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-13 Impact factor: 9.236
Authors: Stephanie A Harmon; Timothy Perk; Christie Lin; Jens Eickhoff; Peter L Choyke; William L Dahut; Andrea B Apolo; John L Humm; Steven M Larson; Michael J Morris; Glenn Liu; Robert Jeraj Journal: J Clin Oncol Date: 2017-06-27 Impact factor: 44.544
Authors: Christie Lin; Tyler Bradshaw; Timothy Perk; Stephanie Harmon; Jens Eickhoff; Ngoneh Jallow; Peter L Choyke; William L Dahut; Steven Larson; John Laurence Humm; Scott Perlman; Andrea B Apolo; Michael J Morris; Glenn Liu; Robert Jeraj Journal: J Nucl Med Date: 2016-07-21 Impact factor: 10.057
Authors: E L Gerety; E M Lawrence; J Wason; H Yan; S Hilborne; J Buscombe; H K Cheow; A S Shaw; N Bird; K Fife; S Heard; D J Lomas; A Matakidou; D Soloviev; T Eisen; F A Gallagher Journal: Ann Oncol Date: 2015-07-22 Impact factor: 32.976
Authors: J C Regelink; P G Raijmakers; N Bravenboer; R Milek; N J Hoetjes; A M de Kreuk; M van Duin; M J Wondergem; P Lips; P Sonneveld; J M Zijlstra; S Zweegman Journal: EJNMMI Res Date: 2016-05-31 Impact factor: 3.138